Results 201 to 210 of about 27,004 (255)

Immunophenotypic, Genetic, and Clinical Features Associated With RUNX1 Mutation in Acute Leukemias and Chronic Myeloid Neoplasms

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 1094-1102, October 2026.
ABSTRACT Introduction RUNX1 is a commonly mutated transcriptional regulator of hematopoiesis in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Mutated RUNX1 (mRUNX1) may associate with cross‐lineage immunophenotypic aberrancy, presenting potential complications for blast lineage assignment at diagnosis. Methods Clinical and laboratory
Yi Han Xia, Eric McGinnis
wiley   +1 more source

Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall. [PDF]

Haematologica
Oster H, Mittelman M.
europepmc   +1 more source

UBE2O as a key regulator of drug-induced erythropoiesis in the context of myelodysplastic syndromes. [PDF]

Blood Adv
Maffeo B, Panuzzo C, Savi A, Itri F, Piccioli S, Danzero AC, Maglione A, Marini S, Voso MT, Fava C, Bracco E, Pergolizzi B, Cilloni D.   +12 more
europepmc   +1 more source

Myelodysplastic syndromes: A primary care perspective. [PDF]

S Afr Fam Pract (2004)
Naidoo K, Parasnath S.
europepmc   +1 more source

Advances and Challenges in the Management of Myelodysplastic Syndromes. [PDF]

Cancers (Basel)
Stempel JM, Kewan T, Zeidan AM.
europepmc   +1 more source

Azacitidine Is Well-Tolerated and Is Associated with High Response Rate in Elderly Patients with Higher-Risk Myelodysplastic Syndromes: A Single Center Observational Study. [PDF]

Cancers (Basel)
Krishnan N, Yanni D, Kogan L, Gerard L, McLean J, Kotchetkov R.   +5 more
europepmc   +1 more source

Donor type and post-transplant outcomes in anti-thymocyte globulin based allogeneic transplantation for myelodysplastic syndromes. [PDF]

Ann Hematol
Park SY, Lee H, Kwag D, Min GJ, Park SS, Yoon JH, Lee SE, Cho BS, Eom KS, Kim HJ, Min CK, Cho SG, Park S, Kim YJ.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Myelodysplastic syndromes

Hematology and Cell Therapy, 1996
The authors review the epidemiological biological, diagnostic, prognostic and therapeutic aspects of myelodysplastic syndromes.
J F, San Miguel, G F, Sanz, T, Vallespí, M C, del Cañizo, M A, Sanz   +4 more
  +9 more sources

Myelodysplastic Syndromes

Annals of the New York Academy of Sciences, 2004
Abstract: Efforts made during the last few years have helped unravel the complex pathogenesis of the myelodysplastic syndromes (MDS). A large number of studies, made possible by the introduction of newer technologies, have led to major progress in understanding the heterogeneous genetic and biological abnormalities contributing to the development and ...
CILLONI, Daniela, MESSA F, CARTURAN S, ARRUGA F, DEFILIPPI I, MESSA E, GOTTARDI E, SAGLIO, Giuseppe   +7 more
  +8 more sources

Myelodysplastic syndromes

Nature Reviews Disease Primers, 2022
Myelodysplastic syndromes (MDS) are a family of myeloid cancers with diverse genotypes and phenotypes characterized by ineffective haematopoiesis and risk of transformation to acute myeloid leukaemia (AML). Some epidemiological data indicate that MDS incidence is increasing in resource-rich regions but this is controversial.
Huan Li, Fang Hu, Robert Peter Gale, Mikkael A. Sekeres, Yang Liang   +4 more
openaire   +2 more sources